Therefore, in the present study, we evaluated the efficacy of two novel C‐terminal inhibitors in targeting chemo‐resistance pathways in melanoma cells resistant to BRAF‐ and MEK‐inhibitors. The gene discussed is BRAF; the disease is melanoma.